| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/18/2002 | CN1370080A NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer |
| 09/18/2002 | CN1370074A Method of treating malignancies and viral infections and improving immune function with dietary supplement |
| 09/18/2002 | CN1370073A Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 09/18/2002 | CN1370069A Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes |
| 09/18/2002 | CN1370067A Use of monoamine oxidase inhibitors for manufacture of drugs intended for treatment of obesity |
| 09/18/2002 | CN1370066A Methods and compsns. for regulating gut motility and food intake |
| 09/18/2002 | CN1370050A Fat or oil compsn. |
| 09/18/2002 | CN1370044A Nitric oxide donors for inducing neurogenesis |
| 09/17/2002 | US6451853 Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity |
| 09/17/2002 | US6451851 Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent |
| 09/17/2002 | US6451829 Coumarinic compounds having IgE affecting properties |
| 09/17/2002 | US6451825 Pharmaceutical agent containing Rho kinase inhibitor |
| 09/17/2002 | US6451808 Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| 09/17/2002 | US6451807 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
| 09/17/2002 | US6451783 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 09/17/2002 | US6451781 Substituted acylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 09/17/2002 | US6451780 Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| 09/17/2002 | US6451777 Method for regulating hair growth |
| 09/17/2002 | US6451771 Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals |
| 09/17/2002 | US6451770 A liquid jet intradermal administration apparatus that administers an immunogenic composition or vaccine to an animal: without a needle, and into the epidermis, dermis and/or hypodermis; wherein the apparatus includes an |
| 09/17/2002 | US6451765 Methods for treating breast cancer using Mammastatin |
| 09/17/2002 | US6451575 The invention is directed to the family of aggrecan degrading metallo proteases (admps) that exhibit the ability to cleave the aggrecan core protein between amino acid residues glu.sup.373 -ala.sup.374. the invention encompasses the |
| 09/17/2002 | US6451541 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc |
| 09/17/2002 | US6451523 Variant form of the receptor for the obese gene product. the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. |
| 09/17/2002 | US6451354 Natural product composition for decreasing IgE production and treating secondary allergic responses |
| 09/17/2002 | US6451335 Formulations and methods for providing prolonged local anesthesia |
| 09/17/2002 | US6451311 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free n-procalcitonin; used as an in vitro or in vivo diagnostic agent |
| 09/17/2002 | US6451288 Method of treating lung diseases with uridine 5′-diphosphate and analogs thereof |
| 09/17/2002 | US6451286 Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| 09/17/2002 | CA2260007C Method for treating gastrointestinal damage |
| 09/17/2002 | CA2184594C Antitussive composition containing an antitussive and benzydamine |
| 09/15/2002 | CA2373454A1 Recombinant infectious laryngotracheitis virus vaccine |
| 09/12/2002 | WO2002071064A1 Method of examining steroid-responsiveness |
| 09/12/2002 | WO2002070742A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | WO2002070741A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | WO2002070737A2 Compositions and methods relating to osteoarthritis |
| 09/12/2002 | WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 09/12/2002 | WO2002070706A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | WO2002070670A1 Novel lactobacillus reuteri useful as probiotics |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070657A2 93870, a human g-protein coupled receptor and uses therefor |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070555A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 09/12/2002 | WO2002070515A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | WO2002070509A2 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | WO2002070494A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
| 09/12/2002 | WO2002070486A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 09/12/2002 | WO2002070070A2 Compositions having improved bioavailability of eletriptan |
| 09/12/2002 | WO2002070010A1 Graft rejection inhibitors |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002070007A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | WO2002070001A2 Use of lp82 to treat hematopoietic disorders |
| 09/12/2002 | WO2002069995A2 Use of trail and antiprogestins for treating cancer |
| 09/12/2002 | WO2002069994A2 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 09/12/2002 | WO2002069987A2 Agent for treating diabetes mellitus |
| 09/12/2002 | WO2002069985A2 Immune response potentiation |
| 09/12/2002 | WO2002069979A2 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
| 09/12/2002 | WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | WO2002069968A1 New use |
| 09/12/2002 | WO2002069966A1 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 09/12/2002 | WO2002069964A1 Enteral formulation |
| 09/12/2002 | WO2002069960A2 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 09/12/2002 | WO2002069950A2 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5 |
| 09/12/2002 | WO2002069949A2 Combination therapy for reduction of toxycity of chemotherapeutic agents |
| 09/12/2002 | WO2002069948A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | WO2002069947A2 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer |
| 09/12/2002 | WO2002069945A2 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 09/12/2002 | WO2002069944A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists |
| 09/12/2002 | WO2002069943A2 Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies |
| 09/12/2002 | WO2002069941A1 Transdermal therapeutic system for the administration of partial dopamine-d2 agonists |
| 09/12/2002 | WO2002069937A1 Compounds and compositions for delivering active agents |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069929A1 Trifunctional systems for chronic illnesses |
| 09/12/2002 | WO2002069925A2 Use of $g(a)-lipoic acid in cosmetic or dermatological preparations |
| 09/12/2002 | WO2002069913A1 Skin-improving composition set |
| 09/12/2002 | WO2002069908A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 09/12/2002 | WO2002069906A2 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | WO2002069905A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | WO2002069903A2 Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| 09/12/2002 | WO2002069901A2 Cathepsin cysteine protease inhibitors |
| 09/12/2002 | WO2002069893A2 Treatment of neurological disease |
| 09/12/2002 | WO2002053099A3 Methods and compositions for treating periodontal disease |
| 09/12/2002 | WO2002048122A3 Benzamidine derivatives |
| 09/12/2002 | WO2002044113A3 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/12/2002 | WO2002043742A8 Cyclodextrins and reversal of atherosclerosis |
| 09/12/2002 | WO2002028862A3 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 09/12/2002 | WO2002017735A3 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 09/12/2002 | WO2002007748A3 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 09/12/2002 | WO2002002096A3 Oral compositions comprising host-response modulating agent |
| 09/12/2002 | WO2001091770A3 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 09/12/2002 | WO2001091768A3 Compositions for treating brain disorders and enhancing brain function, containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 09/12/2002 | WO2001091741A3 Compositions containing hexitol and an antiproliferative agent |
| 09/12/2002 | WO2001089530A3 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |